FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310119413> ?p ?o ?g. }

• W4310119413 endingPage "136" @default.
• W4310119413 startingPage "135" @default.
• W4310119413 abstract "Background: Gemtuzumab ozogamicin (GO) is a CD33-directed antibody-drug conjugate approved for the treatment of newly diagnosed (ND) and refractory/relapsed CD33-positive acute myeloid leukemia (AML). Meta-analysis of individual patient (pt) data from 5 randomized controlled trials (n=3325) confirmed a significant survival benefit of GO added to intensive induction chemotherapy for pts with AML without adverse cytogenetics. While favorable-risk ND-AML pts, specifically core-binding factor AML (CBF-AML), particularly benefited with a 5-year overall survival (OS) improvement of 20.7% (log rank p= 0.0006), pts with intermediate-risk AML also showed a significant 5-yr survival improvement of 5.7% (p=0.005) (Hills RK et al Lancet Oncol 2014: 15, 986). However, the smaller difference in these latter pts coupled with apprehension for risk of sinusoidal obstruction syndrome (SOS) following hematopoietic stem cell transplantation (HSCT) has led many clinicians to not use 7+3 plus GO in the intermediate-risk AML population. Aim/Objective: To perform a retrospective analysis of outcomes of 7+3 plus GO vs 7+3 in ND intermediate-risk cytogenetic AML pts treated at a single comprehensive cancer center. Methods: We studied the demographic, clinical and genetic data of intermediate risk ND-AML pts treated at Roswell Park Comprehensive Cancer Center (n=113) between 2015-2022. Conventional cytogenetics and fluorescence in situ hybridization (FISH) were performed. Genomic profiling was performed using next-generation sequencing methods (FoundationOne®CDx). Risk stratification was defined per the European LeukemiaNet (ELN)-2017 classification. 7+3 plus GO pts received at least one dose of GO 3 mg/m2 (up to one 4.5 mg vial) plus cytarabine 100 mg/m² continuous IV infusion on days 1-7, and daunorubicin 60 mg/m² IV on days 1-3 (7+3). Control pts received 7+3 alone. Prophylactic heparin was administered to prevent hepatic SOS based on institutional standards if not thrombocytopenic. Outcomes included response rate to induction, successful bridging to HSCT, relapse rate, and overall survival. Results: 113 intermediate-risk ND-AML pts were studied: 33 received 7+3 plus GO and 80 received 7+3. Median age was 57 vs. 59 years, respectively (range: 19-76 years). Moreover, there was no significant difference in the percentage of pts > 60 yrs (45% vs 48%). Gender was equally distributed. Pts treated with 7+3 plus GO had a significantly higher rate (p=0.019) of complete remission (CR) and complete remission with incomplete count recovery (CRi) (27/33, 82%) than 7+3 (44/80, 55%; Figure 1A). Among pts with available minimal residual disease (MRD) status detected by multiparameter flow cytometry, 100% achieved MRD-negative status after 7+3 plus GO (18/18) compared to 86% with 7+3 (12/14). Non-responders to 7+3 plus GO were enriched for ASXL1, DNMT3A, TET2, and TP53 mutations as compared to responders who harbored more FLT3, IDH1/2, KRAS/NRAS and RUNX1 mutations. Among pts achieving CR/CRi, 48% after 7+3 plus GO vs 30% after 7+3 (p=0.13) were successfully bridged to HSCT. Cumulative incidence of relapse after CR/CRi was significantly lower after 7+3 plus GO (11%) than 7+3 (43%; p=0.007). Finally, 7+3 plus GO pts demonstrated a superior, yet not statistically significant, median overall survival (OS) benefit (median OS not reached) compared to 7+3 alone (median OS = 35 months; Figure 1B). No pts receiving 7+3 plus GO developed SOS. Conclusions: Intermediate risk ND-AML pts treated with 7+3 plus GO at our academic center had significantly higher rates of MRD-negative CR and CRi, lower rates of relapse, and higher percentage of pts receiving HSCT as compared with 7+3 alone. Non-responders in the 7+3 plus GO group harbored adverse risk genetic mutations that likely dictated the failure to response. Although addition of GO was associated with a non-significant trend towards improved overall survival, longer follow-up is warranted to decipher an absolute survival advantage of this regimen. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310119413 created "2022-11-30" @default.
• W4310119413 creator A5025571948 @default.
• W4310119413 creator A5026722303 @default.
• W4310119413 creator A5029064469 @default.
• W4310119413 creator A5030601713 @default.
• W4310119413 creator A5032765285 @default.
• W4310119413 creator A5038321186 @default.
• W4310119413 creator A5038660651 @default.
• W4310119413 creator A5044821966 @default.
• W4310119413 creator A5046140518 @default.
• W4310119413 creator A5053717205 @default.
• W4310119413 creator A5058062108 @default.
• W4310119413 creator A5058794688 @default.
• W4310119413 creator A5060452476 @default.
• W4310119413 creator A5063315377 @default.
• W4310119413 creator A5075042964 @default.
• W4310119413 creator A5078182330 @default.
• W4310119413 creator A5078571628 @default.
• W4310119413 creator A5080354454 @default.
• W4310119413 creator A5087865615 @default.
• W4310119413 date "2022-11-15" @default.
• W4310119413 modified "2023-10-16" @default.
• W4310119413 title "Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia" @default.
• W4310119413 doi "https://doi.org/10.1182/blood-2022-168482" @default.
• W4310119413 hasPublicationYear "2022" @default.
• W4310119413 type Work @default.
• W4310119413 citedByCount "0" @default.
• W4310119413 crossrefType "journal-article" @default.
• W4310119413 hasAuthorship W4310119413A5025571948 @default.
• W4310119413 hasAuthorship W4310119413A5026722303 @default.
• W4310119413 hasAuthorship W4310119413A5029064469 @default.
• W4310119413 hasAuthorship W4310119413A5030601713 @default.
• W4310119413 hasAuthorship W4310119413A5032765285 @default.
• W4310119413 hasAuthorship W4310119413A5038321186 @default.
• W4310119413 hasAuthorship W4310119413A5038660651 @default.
• W4310119413 hasAuthorship W4310119413A5044821966 @default.
• W4310119413 hasAuthorship W4310119413A5046140518 @default.
• W4310119413 hasAuthorship W4310119413A5053717205 @default.
• W4310119413 hasAuthorship W4310119413A5058062108 @default.
• W4310119413 hasAuthorship W4310119413A5058794688 @default.
• W4310119413 hasAuthorship W4310119413A5060452476 @default.
• W4310119413 hasAuthorship W4310119413A5063315377 @default.
• W4310119413 hasAuthorship W4310119413A5075042964 @default.
• W4310119413 hasAuthorship W4310119413A5078182330 @default.
• W4310119413 hasAuthorship W4310119413A5078571628 @default.
• W4310119413 hasAuthorship W4310119413A5080354454 @default.
• W4310119413 hasAuthorship W4310119413A5087865615 @default.
• W4310119413 hasBestOaLocation W43101194131 @default.
• W4310119413 hasConcept C10205521 @default.
• W4310119413 hasConcept C126322002 @default.
• W4310119413 hasConcept C143998085 @default.
• W4310119413 hasConcept C176290653 @default.
• W4310119413 hasConcept C177713679 @default.
• W4310119413 hasConcept C2776611710 @default.
• W4310119413 hasConcept C2776694085 @default.
• W4310119413 hasConcept C2778041864 @default.
• W4310119413 hasConcept C2778336483 @default.
• W4310119413 hasConcept C2778461978 @default.
• W4310119413 hasConcept C2778623314 @default.
• W4310119413 hasConcept C2778729363 @default.
• W4310119413 hasConcept C28328180 @default.
• W4310119413 hasConcept C54355233 @default.
• W4310119413 hasConcept C71924100 @default.
• W4310119413 hasConcept C86803240 @default.
• W4310119413 hasConceptScore W4310119413C10205521 @default.
• W4310119413 hasConceptScore W4310119413C126322002 @default.
• W4310119413 hasConceptScore W4310119413C143998085 @default.
• W4310119413 hasConceptScore W4310119413C176290653 @default.
• W4310119413 hasConceptScore W4310119413C177713679 @default.
• W4310119413 hasConceptScore W4310119413C2776611710 @default.
• W4310119413 hasConceptScore W4310119413C2776694085 @default.
• W4310119413 hasConceptScore W4310119413C2778041864 @default.
• W4310119413 hasConceptScore W4310119413C2778336483 @default.
• W4310119413 hasConceptScore W4310119413C2778461978 @default.
• W4310119413 hasConceptScore W4310119413C2778623314 @default.
• W4310119413 hasConceptScore W4310119413C2778729363 @default.
• W4310119413 hasConceptScore W4310119413C28328180 @default.
• W4310119413 hasConceptScore W4310119413C54355233 @default.
• W4310119413 hasConceptScore W4310119413C71924100 @default.
• W4310119413 hasConceptScore W4310119413C86803240 @default.
• W4310119413 hasIssue "Supplement 1" @default.
• W4310119413 hasLocation W43101194131 @default.
• W4310119413 hasOpenAccess W4310119413 @default.
• W4310119413 hasPrimaryLocation W43101194131 @default.
• W4310119413 hasRelatedWork W1583871986 @default.
• W4310119413 hasRelatedWork W2016381406 @default.
• W4310119413 hasRelatedWork W2056567560 @default.
• W4310119413 hasRelatedWork W2108413184 @default.
• W4310119413 hasRelatedWork W2120530590 @default.
• W4310119413 hasRelatedWork W2383814905 @default.
• W4310119413 hasRelatedWork W2398920749 @default.
• W4310119413 hasRelatedWork W2406230970 @default.
• W4310119413 hasRelatedWork W2461234028 @default.
• W4310119413 hasRelatedWork W2901880577 @default.
• W4310119413 hasVolume "140" @default.
• W4310119413 isParatext "false" @default.
• W4310119413 isRetracted "false" @default.

• next